%0 Journal Article %A Kristina Gaietto %A Megan Culler Freeman %A Leigh Anne DiCicco %A Sherry Rauenswinter %A Joseph R Squire %A Zachary Aldewereld %A Jennifer Iagnemma %A Brian T Campfield %A David Wolfson %A Traci M Kazmerski %A Erick Forno %T Childhood Asthma and COVID-19: A Nested Case-Control Study %D 2021 %R 10.1101/2021.09.20.21263838 %J medRxiv %P 2021.09.20.21263838 %X Background Most pediatric studies of asthma and COVID-19 to date have been ecological, which offer limited insight. We evaluated the association between asthma and COVID-19 at an individual level.Methods Using data from prospective clinical registries, we conducted a nested case-control study comparing three groups: children with COVID-19 and underlying asthma (“A+C” cases); children with COVID-19 without underlying disease (“C+” controls); and children with asthma without COVID-19 (“A+” controls).Results The cohort included 142 A+C cases, 1110 C+ controls, and 140 A+ controls. A+C cases were more likely than C+ controls to present with dyspnea and wheezing, to receive pharmacologic treatment including systemic steroids (all p<0.01), and to be hospitalized (4.9% vs 1.7%, p=0.01). In the adjusted analysis, A+C cases were nearly 4 times more likely to be hospitalized than C+ controls (adjusted OR=3.95 [95%CI=1.4-10.9]); however, length of stay and respiratory support level did not differ between groups. Among A+C cases, 8.5% presented with an asthma exacerbation and another 6.3% developed acute exacerbation symptoms shortly after testing positive for SARS-CoV-2. Compared to historic A+ controls, A+C cases had less severe asthma, were less likely to be on controller medications, and had better asthma symptom control (all p<0.01).Conclusions In our cohort, asthma was a risk factor for hospitalization in children with COVID-19, but not for worse COVID-19 outcomes. SARS-CoV-2 does not seem to be a strong trigger for pediatric asthma exacerbations. Asthma severity was not associated with higher risk of COVID-19.Key messages In this pediatric cohort, asthma was a risk factor for hospitalization in children with COVID-19, but not for worse COVID-19 outcomes. Baseline asthma severity was not associated with higher risk of COVID-19, and SARS-CoV-2 did not seem to be a strong trigger for pediatric asthma exacerbations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Gaietto's contribution was funded in part by grant number T32-HL129949 from the U.S. National Institutes of Health (NIH). Dr. Forno's contribution was funded in part by grant R01-HL149693 from the U.S. NIH. The funding agencies had no role in the study or the preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The WPACR and the CHP Asthma Registry are both approved by the Institutional Review Board at the University of Pittsburgh (protocols STUDY20110072 and STUDY19020359, respectively).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be requested from the authors, after final peer-reviewed publication and contingent on the necessary ethics / institutional review board approvals. %U https://www.medrxiv.org/content/medrxiv/early/2021/09/22/2021.09.20.21263838.full.pdf